LINC02147: A Potential Drug Target and Biomarker (G102467224)

Target Name: LINC02147

NCBI ID: G102467224

LINC02147

Other Name(s): Long intergenic non-protein coding RNA 2147 | long intergenic non-protein coding RNA 2147

LINC02147: A Potential Drug Target and Biomarker

Long intergenic non-protein coding RNAs (lncNPs) have emerged as a promising source of novel genetic information in recent years. These RNAs are generated from genomic regions that are not typically involved in protein coding, yet they often play important roles in gene regulation and are involved in the development and progression of various diseases. One of the most well-studied lncNPs is LINC02147, which has been shown to be involved in a variety of physiological processes and is considered a potential drug target and biomarker.

LINC02147 is a transcribed RNA molecule that is derived from genomic region 12q34.2. It is characterized by a unique 5'-end signature that consists of a GAAATG repeat followed by a single-base insertion of a uracil residue. This repetitive sequence is present in the genes that encode the major classes of RNA molecules, including ribosomal RNA (rRNA), transfer RNA (tRNA), and microRNA (miRNA), as well as other non-coding RNAs.

Several studies have identified LINC02147 as being involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation. For example, LINC02147 has been shown to be a positive regulator of the cell cycle and has been linked to the G1/S transition. Additionally, LINC02147 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells respond to environmental stressors and perform programmed cell death.

In addition to its role in cell regulation, LINC02147 has also been shown to be involved in the regulation of gene expression. For example, LINC02147 has been shown to play a role in the regulation of the expression of the genes involved in cell adhesion, as well as the development and progression of various diseases.

Given the complexity of LINC02147's function and its potential involvement in a variety of cellular processes, it has attracted significant interest as a potential drug target. Many studies have been conducted to investigate the effects of drugs on LINC02147 expression and its function. These studies have led to the identification of several potential drug targets for LINC02147, including those involved in cell adhesion, cell cycle regulation, and apoptosis.

One of the most promising potential drug targets for LINC02147 is the protein known as PDCD1 (Protamineuron). PDCD1 is a protein that is involved in the regulation of mitochondrial function and has been shown to be a negative regulator of LINC02147. Studies have shown that PDCD1 inhibition can lead to increased LINC02147 expression and cell proliferation, suggesting that PDCD1 may be a useful target for LINC02147.

Another potential drug target for LINC02147 is the protein known as p53. p53 is a well-known protein that is involved in the regulation of DNA damage repair and has been shown to play a negative role in LINC02147 expression. Studies have shown that p53 inhibition can lead to decreased LINC02147 expression and cell growth, suggesting that p53 may be a useful target for LINC02147.

In addition to its potential drug targets, LINC02147 has also been shown to be a potential biomarker for various diseases. For example, LINC02147 has been shown to be downregulated in various cancer types, including breast, ovarian, and prostate cancer. Additionally, LINC02147 has been shown to be involved in

Protein Name: Long Intergenic Non-protein Coding RNA 2147

The "LINC02147 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02147 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets